title: Prognostic factors after liver resection for hepatocellular carcinoma: a single-center experience from China.
abstract: BACKGROUND
  This study aimed to clarify the risk factors for survival and recurrence of hepatocellular carcinoma (HCC) in a cohort of Chinese HCC patients after hepatectomy and to compare 6 developed staging systems.
  
  
  METHODS
  A retrospective analysis was performed on 165 consecutive patients. The Kaplan-Meier method was used to calculate survival. Postoperative prognostic factors were evaluated using univariate and multivariate analyses. The overall predictive power of each staging system was evaluated by the area under the receiver operating characteristic curve.
  
  
  RESULTS
  The overall survival rates of 1, 3, and 5 years were 81.2%, 58.6%, and 56.7%, respectively, and the corresponding disease-free survival rates were 52.9%, 23.3%, and 15.5%, respectively. α-fetoprotein level and blood transfusion were correlated significantly with patients' overall survival, and portal vein thrombosis and tumor size (>5 cm) were correlated significantly with poor disease-free survival.
  
  
  CONCLUSIONS
  The French staging system is better for predicting the prognosis of HCC patients receiving surgical treatment.
authors.affiliation: Department of Liver Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shuai-fu-yuan 1, Wang-fu-jing, Beijing, 100730, China.
authors.forename: Liguo
authors.initials: L
authors.lastname: Liu
authors.forename: Ruoyu
authors.initials: R
authors.lastname: Miao
authors.forename: Huayu
authors.initials: H
authors.lastname: Yang
authors.forename: Xin
authors.initials: X
authors.lastname: Lu
authors.forename: Yi
authors.initials: Y
authors.lastname: Zhao
authors.forename: Yilei
authors.initials: Y
authors.lastname: Mao
authors.forename: Shouxian
authors.initials: S
authors.lastname: Zhong
authors.forename: Jiefu
authors.initials: J
authors.lastname: Huang
authors.forename: Xinting
authors.initials: X
authors.lastname: Sang
authors.forename: Haitao
authors.initials: H
authors.lastname: Zhao
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000627:therapeutic use; D006528:Carcinoma, Hepatocellular / Q000188:drug therapy / Q000401:mortality / Q000473:pathology / Q000601:surgery*; D017024:Chemotherapy, Adjuvant; D002681:China; D005260:Female; D005500:Follow-Up Studies; D006498:Hepatectomy; D006801:Humans; D008113:Liver Neoplasms / Q000188:drug therapy / Q000401:mortality / Q000473:pathology / Q000601:surgery*; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D009364:Neoplasm Recurrence, Local / Q000453:epidemiology; D009367:Neoplasm Staging / Q000379:methods*; D012372:ROC Curve; D012189:Retrospective Studies; D012307:Risk Factors; D016019:Survival Analysis; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents